Your browser doesn't support javascript.
loading
Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.
Zschäbitz, Stefanie; Erlmeier, Franziska; Stöhr, Christine; Herrmann, Edwin; Polifka, Iris; Agaimy, Abbas; Trojan, Lutz; Ströbel, Philipp; Becker, Frank; Wülfing, Christian; Barth, Peter; Stöckle, Michael; Staehler, Michael; Stief, Christian; Haferkamp, Axel; Hohenfellner, Markus; Macher-Göppinger, Stephan; Wullich, Bernd; Noldus, Joachim; Brenner, Walburgis; Roos, Frederik C; Walter, Bernhard; Otto, Wolfgang; Burger, Maximilian; Schrader, Andres Jan; Mondorf, Yvonne; Hartmann, Arndt; Ivanyi, Philipp; Steffens, Sandra.
Afiliación
  • Zschäbitz S; Dept. of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Erlmeier F; Institute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.
  • Stöhr C; Institute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.
  • Herrmann E; Department of Urology, University Hospital Münster, 48149 Münster, Germany.
  • Polifka I; Present address: Institute of Urology, Prosper-Hospital GmbH, 45659 Recklinghausen, Germany.
  • Agaimy A; Institute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.
  • Trojan L; Institute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), 91054 Erlangen, Germany.
  • Ströbel P; Department of Urology, University Hospital Göttingen, 37075 Göttingen, Germany.
  • Becker F; Institute of Pathology, University Hospital Göttingen, 37075 Göttingen, Germany.
  • Wülfing C; Department of Urology and Pediatric Urology, University Hospital Saarland (UKS), 66421 Homburg, Germany.
  • Barth P; Present address: Urological Group and Clinic Derouet/Pönicke/Becker, Boxberg Centre, 66538 Neunkirchen, Germany.
  • Stöckle M; Department of Urology, University Hospital Münster, 48149 Münster, Germany.
  • Staehler M; Present address: Department of Urology, Asklepios Clinics Altona, 22763 Hamburg, Germany.
  • Stief C; Department of Urology, University Hospital Marburg, 35037 Marburg, Germany.
  • Haferkamp A; Present address: Institute of Pathology/Gerhard-Domagk Institute, University Hospital Münster, 48149 Münster, Germany.
  • Hohenfellner M; Department of Urology and Pediatric Urology, University Hospital Saarland (UKS), 66421 Homburg, Germany.
  • Macher-Göppinger S; Department of Urology, University Hospital Munich, 81337 Munich, Germany.
  • Wullich B; Department of Urology, University Hospital Munich, 81337 Munich, Germany.
  • Noldus J; Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Brenner W; Present address: Department of Urology and Pediatric Urology, University Hospital Mainz, 55131 Mainz, Germany.
  • Roos FC; Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Walter B; Institute of Pathology, University Hospital Mainz, 55131 Mainz, Germany.
  • Otto W; Department of Urology and Pediatric Urology, University Hospital Erlangen, 91058 Erlangen, Germany.
  • Burger M; Department of Urology, Marien-Hospital Herne, Ruhr University Bochum, 44625 Herne, Germany.
  • Schrader AJ; Department of Urology, University Hospital Mainz, 55131 Mainz, Germany.
  • Mondorf Y; Present address: Department of Gynecology, University Hospital Mainz, 55131 Mainz, Germany.
  • Hartmann A; Department of Urology, University Hospital Frankfurt, 60590 Frankfurt/Main, Germany.
  • Ivanyi P; Department of Urology and Pediatric Urology, University Hospital Erlangen, 91058 Erlangen, Germany.
  • Steffens S; Present address: Department of Urology, Kreiskliniken Altötting-Burghausen, 84489 Burghausen, Germany.
J Cancer ; 13(6): 1706-1712, 2022.
Article en En | MEDLINE | ID: mdl-35399715
Prostate specific membrane antigen (PSMA) is an emerging diagnostic and therapeutic target in prostate cancer. 68Ga-PSMA-labeled hybrid imaging is used for the detection of prostate primary tumors and metastases. Therapeutic applications such as Lutetium-177 PSMA radionuclide therapy or bispecific antibodies that target PSMA are currently under investigation within clinical trials. The expression of PSMA, however, is not specific to prostate-tissue. It has been described in the neovascular endothelium of different types of cancer such as breast cancer, and clear cell renal cell carcinoma (ccRCC). The aim of this study was to analyze PSMA expression in papillary RCC (pRCC) type 1 and type 2, the most common non-ccRCC subtypes, and to evaluate the potential of PSMA-targeted imaging and treatment in pRCC. Formalin-fixed, paraffin-embedded tissue samples of primary tumors were analyzed for PSMA expression by immunohistochemistry. Out of n=374 pRCC specimens from the multicenter PANZAR consortium, n=197 pRCC type 1 and n=110 type 2 specimens were eligible for analysis and correlated with clinical data. In pRCC type 1 PSMA staining was positive in 4 of 197 (2.0%) samples whereas none (0/110) of the pRCC type 2 samples were positive for PSMA in this large cohort of pRCC patients. No significant PSMA expression was detected in pRCC. Reflecting current clinical evaluation of PMSA expression in RCC do not encourage further analysis in papillary subtypes.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Alemania